Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models-Reference-Cited by-同舟云学术

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

Published:2019-02-12 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Wang Zebin,Sun Kaiming,Xiao Yonghong,Feng Bin,Mikule Keith,Ma XiaoYan,Feng Ningping,Vellano Christopher P.,Federico Lorenzo,Marszalek Joseph R.,Mills Gordon B.,Hanke Jeffrey,Ramaswamy Sridhar,Wang Jing

Funder

TESARO Inc

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-38534-6.pdf

Reference54 articles.

1. Vyas, S. & Chang, P. New PARP targets for cancer therapy. Nat Rev Cancer 14, 502–509, https://doi.org/10.1038/nrc3748 (2014).

2. Pommier, Y., O’Connor, M. J. & de Bono, J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med 8, 362ps317, https://doi.org/10.1126/scitranslmed.aaf9246 (2016).

3. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917, https://doi.org/10.1038/nature03443 (2005).

4. Murai, J. et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 72, 5588–5599, https://doi.org/10.1158/0008-5472CAN-12-2753 (2012).

5. Mirza, M. R. et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 375, 2154–2164, https://doi.org/10.1056/NEJMoa1611310 (2016).

Cited by 193 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Microsatellite Instability-High and High Tumor Mutation Burden Frequencies in Urologic Malignancies Off-Label for Immune Checkpoint Inhibitors in Japan: A Retrospective Single-Institutional Cohort;Cureus;2024-09-13

2. Claudin-4 remodeling of nucleus-cell cycle crosstalk maintains ovarian tumor genome stability and drives resistance to genomic instability-inducing agents;2024-09-07

3. Reversal of T-cell exhaustion: Mechanisms and synergistic approaches;International Immunopharmacology;2024-09

4. Adaptive Responses to PARP Inhibition Predict Response to Olaparib and Durvalumab: Multi-omic Analysis of Serial Biopsies in the AMTEC Trial;2024-08-30

5. Strategies for the prevention or reversal of PARP inhibitor resistance;Expert Review of Anticancer Therapy;2024-08-20